Iovance Biotherapeutics Inc. announced that Chief Financial Officer Jean-Marc Bellemin will resign from his position effective July 10, 2025. Bellemin, who has served as the principal financial and accounting officer since November 2020, is leaving to pursue other opportunities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059464), on June 13, 2025, and is solely responsible for the information contained therein.